Novo Nordisk enters bidding war with Pfizer over U.S. biotech Metsera

Novo Nordisk has launched a superior, aggressive bid of up to $8.5 billion, including $6 billion upfront, for U.S. obesity biotech firm Metsera, outbidding Pfizer's $7.3 billion offer. This strategic move, following recent board changes at Novo Nordisk, underscores its intensified efforts to build a next-generation obesity and diabetes pipeline ahead of semaglutide patent expiry and secure market leadership in the rapidly growing $150 billion obesity drug sector, where it competes with Eli Lilly. Pfizer has criticized the bid as "reckless" and anti-competitive, raising potential antitrust concerns, while Metsera's shares surged on the news, reflecting the high stakes in acquiring its experimental weight-loss drug portfolio.

Analysis

Novo Nordisk (NVO) has launched a superior bid of up to $8.5 billion, including $6 billion upfront, for U.S. obesity biotech Metsera (MTSR), outbidding Pfizer's (PFE) $7.3 billion offer. Metsera's board deemed Novo's offer "superior," valuing the company at up to $77.75 per share, totaling approximately $9 billion, and has given Pfizer four business days to respond. Metsera shares surged nearly 100% year-to-date and jumped over 19% premarket, reflecting the significant premium.

This aggressive move by Novo is a strategic imperative to bolster its next-generation diabetes and obesity pipeline, aligning with new CEO Mike Doustdar's objectives and addressing prior board concerns regarding market pace. The acquisition aims to secure future growth ahead of semaglutide patent expiry, leveraging Metsera's experimental GLP-1 and amylin mimic drugs, which analysts project could achieve over $5 billion in peak sales.

The bid intensifies competition in the projected $150 billion obesity market, where Novo competes with Eli Lilly (LLY). Pfizer has vehemently criticized Novo's offer as "reckless" and anti-competitive, citing "substantial regulatory and executional risk" and potential antitrust violations. This suggests significant regulatory scrutiny and potential for further bidding escalation or legal challenges.

Key Decisions for Investors

• Monitor Pfizer's response within the four-day negotiation window, as a potential counter-bid or withdrawal will significantly impact Metsera's valuation and the competitive dynamics in the obesity market.
• Evaluate the heightened antitrust risk associated with Novo Nordisk's aggressive bid, as regulatory challenges could introduce delays or complications for the deal's closure and its implications for market competition.
• Assess Novo Nordisk's long-term pipeline strength and market leadership, considering the strategic importance of Metsera's experimental drugs for sustained growth beyond semaglutide's patent expiry.